Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

IMPORTANCE: Limited information is available on the safety of a rechallenge with an immune checkpoint inhibitor (ICI) after an immune-related adverse event (irAE). OBJECTIVE: To identify the recurrence rate of the same irAE that prompted discontinuation of ICI therapy after an ICI rechallenge in pat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Oncol
Asıl Yazarlar: Dolladille, Charles, Ederhy, Stéphane, Sassier, Marion, Cautela, Jennifer, Thuny, Franck, Cohen, Ariel A., Fedrizzi, Sophie, Chrétien, Basile, Da-Silva, Angélique, Plane, Anne-Flore, Legallois, Damien, Milliez, Paul U., Lelong-Boulouard, Véronique, Alexandre, Joachim
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2020
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7163782/
https://ncbi.nlm.nih.gov/pubmed/32297899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.0726
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller